Merkel cell carcinoma--current therapeutic options.

Area of Science:

• Oncology
• Dermatology
• Neuroendocrinology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer predominantly affecting elderly individuals in sun-exposed areas.
• MCC demonstrates significant radiosensitivity and chemosensitivity.
• Identifying adverse prognostic factors is crucial for tailoring aggressive therapies to high-risk patients.

Purpose of the Study:

• To review prognostic factors and treatment strategies for Merkel cell carcinoma.
• To discuss the role of surgery, radiotherapy, and chemotherapy in managing MCC.
• To highlight the significance of nodal status in predicting recurrence and distant disease.

Main Methods:

• Review of existing literature on Merkel cell carcinoma management.
• Analysis of prognostic factors, particularly nodal involvement.
• Discussion of treatment modalities including surgery, radiotherapy, and chemotherapy.

Main Results:

• The presence of nodal secondaries is the most potent adverse prognostic factor for MCC.
• Local excision is recommended, with radiotherapy potentially obviating the need for wide margins.
• Radiotherapy can serve as a primary treatment for unresectable or frail patients, achieving local control.
• Involved nodes increase the risk of distant disease; chemoradiotherapy is being explored as definitive treatment.
• Adjuvant chemotherapy's role in preventing distant metastases is under investigation.
• Distant MCC disease has a poor prognosis, with chemotherapy offering transient responses.

Conclusions:

• Treatment strategies for Merkel cell carcinoma should be guided by prognostic factors, especially nodal status.
• Multimodality approaches involving surgery, radiotherapy, and potentially chemotherapy are essential for optimal management.
• Further research is needed to clarify the role of adjuvant chemotherapy in reducing distant metastases.